This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alexander Zvulunov, MD
Department of Dermatology Soroka Medical Center Beer-Sheva 84101 Israel

David T. Wyatt, MD; Linda G. Rabinowitz, MD; Nancy B. Esterly, MD
Milwaukee, Wis

Arch Dermatol. 1997;133(6):795-796.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

An accelerated growth rate of acquired melanocytic nevi (AMN) following growth hormone therapy in children raises a concern about the potential risk for melanoma.¹ Survivors of childhood malignancies may have increased numbers of AMN.² Because the number of AMN, rather than their growth rate, is a known risk factor for melanoma,³ we assessed the AMN counts in a cross-sectional study of survivors of childhood neoplasia with secondary growth hormone deficiency (GHD).

Subjects and Methods.

The patient group (group 1) consisted of 20 children (13 males and 7 females) with secondary GHD due to chemotherapy or radiotherapy treated with recombinant human growth hormone (Protropin, Genentech Inc, South San Francisco, Calif) 0.3 mg/kg per week. Prior neoplasms included medulloblastoma (n=7), craniopharyngioma (n=5), histiocytosis x (n=3), astrocytoma (n=2), ependymoma (n=1), meningioma (n=1), and rhabdomyosarcoma (n=1). Chemotherapy was administered to 8 children and radiotherapy was administered to 17 children.

There were . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?